Immuron Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Immuron şirketinin toplam hissedar öz sermayesi A$12.7M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$15.5M ve A$2.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$11.66m
Eşitlik	AU$12.71m
Toplam yükümlülükler	AU$2.84m
Toplam varlıklar	AU$15.55m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Immuron suspends research on COVID-19 program

Aug 19

Immuron says proposed trials of antibacterial drug put on clinical hold by FDA

Jul 26

Immuron to get European patent for drug composition to treat bacterial infection

Jul 07

Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%

Dec 15

Immuron soars 26% on positive vaccine responses in gut mediated pathogens

Nov 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IMRN 'nin kısa vadeli varlıkları ( A$14.7M ) kısa vadeli yükümlülüklerini ( A$2.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: IMRN şirketinin kısa vadeli varlıkları ( A$14.7M ) uzun vadeli yükümlülüklerini ( A$141.5K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IMRN borçsuzdur.

Borcun Azaltılması: IMRN un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IMRN şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: IMRN serbest nakit akışı her yıl % 9.9 1.5 yıl yetecek nakit akışına sahip olacaktır.

Immuron Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Immuron Limited, Annual General Meeting, Oct 28, 2022

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron suspends research on COVID-19 program

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron says proposed trials of antibacterial drug put on clinical hold by FDA

Immuron to get European patent for drug composition to treat bacterial infection

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron soars 26% on positive vaccine responses in gut mediated pathogens

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin